

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Date: July 28, 2015

---

**UBS Group AG**  
Commission File Number: 1-36764

**UBS AG**  
Commission File Number: 1-15060  
(Registrants' Names)

---

**Bahnhofstrasse 45, Zurich, Switzerland, and  
Aeschenvorstadt 1, Basel, Switzerland**  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

---

---

This Form 6-K consists of the UBS Group AG (consolidated) BIS Basel III leverage ratio information as of 30 June 2015, published today by the registrants, which appears immediately following this page.

# UBS Group AG (consolidated) BIS Basel III leverage ratio information

This document provides BIS Basel III leverage ratio information as of 30 June 2015, as required by the revised FINMA Circular 2008 / 22 "Disclosure – banks."

## BIS Basel III leverage ratio disclosure requirements

On 1 January 2015, disclosure requirements for the leverage ratio in accordance with BIS Basel III regulations came into effect in Switzerland, and we are required to disclose BIS Basel III leverage ratio information on a quarterly basis.

The tables in the following section provide BIS Basel III leverage ratio information as of 30 June 2015 according to the current disclosure requirements.

→ Refer to our second quarter 2015 report for information on our Swiss SRB leverage ratio as of 30 June 2015

## BIS Basel III leverage ratio

As of 30 June 2015, our total BIS Basel III leverage ratio was 3.6% on a fully applied basis and 4.3% on a phase-in basis.

The BIS Basel III leverage ratio is calculated by dividing the period-end tier 1 capital by the period-end BIS Basel III total adjusted exposure (BIS Basel III Leverage Ratio Denominator (LRD)), which consists of IFRS on-balance sheet assets and off-balance sheet items adjusted for netting of derivatives, eligible cash variation margin netting, net notional amounts less add-on deductions for written credit derivatives as well as an additional charge for counterparty credit risk related to securities financing transactions.

The BIS Basel III LRD was CHF 949 billion on a fully applied basis and CHF 954 billion on a phase-in basis. The table "Reconciliation of IFRS total assets to BIS Basel III total on-balance sheet exposures excluding derivatives and securities financing transactions" below shows the difference between total IFRS assets per IFRS consolidation scope and on balance sheet exposures, which is shown in the "BIS Basel III leverage ratio common disclosure" table on the next page. The difference is due to the application of the regulatory scope of consolidation. In addition, carrying values for derivative financial instruments and securities financing transactions are deducted from IFRS total assets. They are measured differently under BIS Basel III leverage ratio rules and therefore added back in separate exposure line items in the "BIS Basel III leverage ratio common disclosure" table on the next page.

→ Refer to the "UBS Group AG consolidated supplemental disclosures required under Basel III Pillar 3 regulations" section of our Annual Report 2014, and our UBS Group Basel III Pillar 3 First Half 2015 Report, which will be published by the end of August 2015 in the "Pillar 3, SEC filings & other disclosures" section at [www.ubs.com/investors](http://www.ubs.com/investors) for more information on the regulatory scope of consolidation

→ Refer to our second quarter 2015 report for information on our BIS Basel III leverage ratio movements

## Reconciliation of IFRS total assets to BIS Basel III total on-balance sheet exposures excluding derivatives and securities financing transactions

CHF million	30.6.15
<b>On-balance sheet exposures</b>	
IFRS total assets	950,168
Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for accounting purposes but outside the scope of regulatory consolidation	(17,537)
Adjustment for investments in banking, financial, insurance or commercial entities that are outside the scope of consolidation for accounting purposes but consolidated for regulatory purposes	2
Adjustment for fiduciary assets recognized on the balance sheet pursuant to the operative accounting framework but excluded from the leverage ratio exposure measure	0
Less carrying value of derivative financial instruments in IFRS total assets <sup>1</sup>	(198,619)
Less carrying value of securities financing transactions in IFRS total assets <sup>2</sup>	(105,194)
Adjustments to accounting values	0
<b>On-balance sheet items excluding derivatives and securities financing transactions, but including collateral</b>	<b>628,821</b>
Asset amounts deducted in determining BIS Basel III tier 1 capital	(9,832)
<b>Total on-balance sheet exposures (excluding derivatives and securities financing transactions)</b>	<b>618,988</b>

<sup>1</sup> Consists of positive replacement values and cash collateral receivables on derivative instruments in accordance with the regulatory scope of consolidation. <sup>2</sup> Consists of cash collateral on securities borrowed, reverse repurchase agreements and prime brokerage receivables related to securities financing transactions in accordance with the regulatory scope of consolidation.

## BIS Basel III leverage ratio common disclosure

The naming convention in the following table is based on BIS guidance and does not reflect UBS's naming convention used in our external reports.

<i>CHF million, except where indicated</i>	<b>30.6.15</b>
<b>On-balance sheet exposures</b>	
1 On-balance sheet items excluding derivatives and SFTs <sup>1</sup> , but including collateral	628,821
2 (Asset amounts deducted in determining Basel III tier 1 capital)	(9,832)
<b>3 Total on-balance sheet exposures (excluding derivatives and SFTs<sup>1</sup>)</b>	<b>618,988</b>
<b>Derivative exposures</b>	
4 Replacement cost associated with all derivatives transactions (i.e., net of eligible cash variation margin)	54,284
5 Add-on amounts for PFE <sup>2</sup> associated with all derivatives transactions	104,914
6 Gross-up for derivatives collateral provided where deducted from the balance sheet assets pursuant to the operative accounting framework	882
7 (Deductions of receivables assets for cash variation margin provided in derivatives transactions)	(14,387)
8 (Exempted CCP <sup>3</sup> leg of client-cleared trade exposures)	(15,847)
9 Adjusted effective notional amount of all written credit derivatives <sup>4</sup>	173,175
10 (Adjusted effective notional offsets and add-on deductions for written credit derivatives) <sup>5</sup>	(146,065)
<b>11 Total derivative exposures</b>	<b>156,955</b>
<b>Securities financing transaction exposures</b>	
12 Gross SFT <sup>1</sup> assets (with no recognition of netting), after adjusting for sale accounting transactions	146,502
13 (Netted amounts of cash payables and cash receivables of gross SFT <sup>1</sup> assets)	(41,308)
14 CCR <sup>6</sup> exposure for SFT assets <sup>1</sup>	26,783
15 Agent transaction exposures	0
<b>16 Total securities financing transaction exposures</b>	<b>131,977</b>
<b>Other off-balance sheet exposures</b>	
17 Off-balance sheet exposure at gross notional amount	143,733
18 (Adjustments for conversion to credit equivalent amounts)	(97,610)
<b>19 Total off-balance sheet items</b>	<b>46,123</b>
<b>Total exposures (leverage ratio denominator), phase-in</b>	<b>954,043</b>
(Additional asset amounts deducted in determining Basel III tier 1 capital fully applied)	(4,712)
<b>Total exposures (leverage ratio denominator), fully applied</b>	<b>949,331</b>
<b>Capital and total exposures (leverage ratio denominator), phase-in</b>	
20 Tier 1 capital	40,593
21 Total exposures (leverage ratio denominator)	954,043
<b>Leverage ratio</b>	
<b>22 Basel III leverage ratio phase-in (%)</b>	<b>4.3</b>
<b>Capital and total exposures (leverage ratio denominator), fully applied</b>	
20 Tier 1 capital	34,042
21 Total exposures (leverage ratio denominator)	949,331
<b>Leverage ratio</b>	
<b>22 Basel III leverage ratio fully applied (%)</b>	<b>3.6</b>

<sup>1</sup> Securities financing transactions. <sup>2</sup> Potential future exposure – Current exposure method (CEM add-on) based on notional amounts. <sup>3</sup> Central cleared counterparties. <sup>4</sup> Includes protection sold including agency transactions. <sup>5</sup> Protection sold can be offset with protection bought on the same underlying reference entity provided the conditions according to the Basel III leverage ratio framework and disclosure requirements are met. <sup>6</sup> Counterparty credit risk.

## BIS Basel III leverage ratio summary comparison

The naming convention in the following table is based on BIS guidance and does not reflect UBS's naming convention used in our external reports.

<i>CHF million</i>	<b>30.6.15</b>
1 Total consolidated assets as per published financial statements	950,168
2 Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for accounting purposes but outside the scope of regulatory consolidation <sup>1</sup>	(27,369)
3 Adjustment for fiduciary assets recognised on the balance sheet pursuant to the operative accounting framework but excluded from the leverage ratio exposure measure	0
4 Adjustments for derivative financial instruments	(41,663)
5 Adjustment for securities financing transactions (i.e., repos and similar secured lending)	26,783
6 Adjustment for off-balance sheet items (i.e., conversion to credit equivalent amounts of off-balance sheet exposures)	46,123
7 Other adjustments	2
<b>8 Leverage ratio exposure (leverage ratio denominator), phase-in</b>	<b>954,043</b>

<sup>1</sup> This item includes assets that are deducted from tier 1 capital.

---

**Notice to investors** | This document and the information contained herein are provided solely for information purposes, and are not to be construed as solicitation of an offer to buy or sell any securities or other financial instruments in Switzerland, the United States or any other jurisdiction. No investment decision relating to securities of or relating to UBS Group AG, UBS AG or their affiliates should be made on the basis of this document. Refer to UBS's second quarter 2015 report and its Annual Report 2014 for additional information. These reports are available at [www.ubs.com/investors](http://www.ubs.com/investors).

**Rounding** | Numbers presented throughout this document may not add up precisely to the totals provided in the tables and text. Percentages, percent changes and absolute variances are calculated based on rounded figures displayed in the tables and text and may not precisely reflect the percentages, percent changes and absolute variances that would be derived based on figures that are not rounded.

**Tables** | Within tables, blank fields generally indicate that the field is not applicable or not meaningful, or that information is not available as of the relevant date or for the relevant period. Zero values generally indicate that the respective figure is zero on an actual or rounded basis.

This Form 6-K is hereby incorporated by reference into (1) each of the registration statements of UBS AG on Form F-3 (Registration Number 333-200212) and of UBS Group AG on Form S-8 (Registration Numbers 333-200634; 333-200635; 333-200641; and 333-200665) and Form F-4 (Registration number 333-199011), and into each prospectus outstanding under any of the foregoing registration statements, (2) any outstanding offering circular or similar document issued or authorized by UBS AG that incorporates by reference any Form 6-K's of UBS AG that are incorporated into its registration statements filed with the SEC, and (3) the base prospectus of Corporate Asset Backed Corporation ("CABCO") dated June 23, 2004 (Registration Number 333-111572), the Form 8-K of CABCO filed and dated June 23, 2004 (SEC File Number 001-13444), and the Prospectus Supplements relating to the CABCO Series 2004-101 Trust dated May 10, 2004 and May 17, 2004 (Registration Number 033-91744 and 033-91744-05).

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UBS Group AG

By: /s/ David Kelly

Name: David Kelly

Title: Managing Director

By: /s/ Sarah M. Starkweather

Name: Sarah M. Starkweather

Title: Executive Director

UBS AG

By: /s/ David Kelly

Name: David Kelly

Title: Managing Director

By: /s/ Sarah M. Starkweather

Name: Sarah M. Starkweather

Title: Executive Director

Date: July 28, 2015